Work

A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.2044

Authors: Ulrik Niels Lassen, Morten Mau-Soerensen, Andrew L. Kung, Patrick Y. Wen, Eudocia Quant Lee, Scott R. Plotkin, Aida Muhic, Tami Rashal, Tony Williams, Dilara McCauley, Joel Ellis, Jean-Richard Saint-Martin, Robert Carlson, Ran Frenkel, Sharon Shacham, Mansoor Raza Mirza, Michael Kauffman, Andrew B. Lassman

Institutions: Rigshospitalet, Copenhagen University Hospital, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, Dana-Farber Cancer Institute, Massachusetts General Hospital, Karyopharm Therapeutics (United States)

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4231239683

Cites:

Cited by: 4

Related to: 10